Adeno-Associated Virus Vector for Central Nervous System Gene Therapy

Danqing Zhu¹, Adam J Schieferecke², Paola A Lopez³, David V Schaffer⁴

Affiliations

¹ California Institute for Quantitative Biosciences, University of California, Berkeley, CA, 94720, USA.
² Department of Molecular and Cell Biology, University of California, Berkeley, CA, 94720, USA.
³ Department of Bioengineering, University of California, Berkeley, CA, 94720, USA.
⁴ California Institute for Quantitative Biosciences, University of California, Berkeley, CA, 94720, USA; Department of Molecular and Cell Biology, University of California, Berkeley, CA, 94720, USA; Department of Bioengineering, University of California, Berkeley, CA, 94720, USA; Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA, 94720, USA; Helen Wills Neuroscience Institute, University of California, Berkeley, CA, 94720, USA. Electronic address: schaffer@berkeley.edu.

PMID: 33895085
DOI: 10.1016/j.molmed.2021.03.010

Review

Adeno-Associated Virus Vector for Central Nervous System Gene Therapy

Danqing Zhu et al. Trends Mol Med. 2021 Jun.

. 2021 Jun;27(6):524-537.

doi: 10.1016/j.molmed.2021.03.010. Epub 2021 Apr 21.

Authors

Danqing Zhu¹, Adam J Schieferecke², Paola A Lopez³, David V Schaffer⁴

Affiliations

¹ California Institute for Quantitative Biosciences, University of California, Berkeley, CA, 94720, USA.
² Department of Molecular and Cell Biology, University of California, Berkeley, CA, 94720, USA.
³ Department of Bioengineering, University of California, Berkeley, CA, 94720, USA.
⁴ California Institute for Quantitative Biosciences, University of California, Berkeley, CA, 94720, USA; Department of Molecular and Cell Biology, University of California, Berkeley, CA, 94720, USA; Department of Bioengineering, University of California, Berkeley, CA, 94720, USA; Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA, 94720, USA; Helen Wills Neuroscience Institute, University of California, Berkeley, CA, 94720, USA. Electronic address: schaffer@berkeley.edu.

PMID: 33895085
DOI: 10.1016/j.molmed.2021.03.010

Abstract

The past several years have witnessed significant advances in the development of therapeutic gene delivery for neurological disorders of the central nervous system (CNS). In particular, genome-wide sequencing analysis has deepened our understanding of mutations that underlie many monogenic disorders, which in turn has contributed to clinical advances involving adeno-associated virus (AAV) vector delivery of replacement genes to treat recessive disorders. Moreover, gene therapy has been further bolstered with advances in genome editing tools that allow researchers to silence, repair, and amend endogenous genes. However, despite strong preclinical and clinical progress, challenges remain, including delivery and safety. Here, we discuss advances in AAV engineering, recent developments in cargo design, and translation of these technologies towards clinical progress.

Keywords: AAV; CNS; gene therapy.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Adeno-Associated Virus Vector for Central Nervous System Gene Therapy

Affiliations

Adeno-Associated Virus Vector for Central Nervous System Gene Therapy

Authors

Affiliations

Abstract

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous